(Q37138859)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18413693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

review article

1 reference

title

Valid treatment options for osteoporosis and osteopenia in HIV-infected persons (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18413693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18413693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Laura E Voss

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18413693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Charlott Williams

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18413693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Eric C Daume

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18413693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

language of work or name

English

0 references

publication date

15 April 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18413693%20AND%20SRC:MED&resulttype=core&format=json

Annals of Pharmacotherapy

5 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18413693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18413693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18413693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

670-679

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18413693%20AND%20SRC:MED&resulttype=core&format=json

Bone disease and HIV infection

5 January 2020

cites work

1 reference

An Increased Risk of Osteoporosis during Acquired Immunodeficiency Syndrome

21 January 2018

1 reference

Osteoporosis prevention, diagnosis, and therapy

21 January 2018

1 reference

Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

21 January 2018

1 reference

Bone disorders associated with the human immunodeficiency virus: pathogenesis and management

21 January 2018

1 reference

Osteopenia in HIV-infected women prior to highly active antiretroviral therapy

21 January 2018

1 reference

Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.

21 January 2018

1 reference

Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection

21 January 2018

1 reference

Testosterone replacement therapy for bone loss prevention in HIV-infected males

21 January 2018

1 reference

Comparing Therapies for Postmenopausal Osteoporosis Prevention and Treatment

21 January 2018

1 reference

Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International

21 January 2018

1 reference

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis

21 January 2018

1 reference

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

21 January 2018

1 reference

Mechanisms of anabolic therapies for osteoporosis

21 January 2018

1 reference

Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men.

21 January 2018

1 reference

Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis

21 January 2018

1 reference

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

21 January 2018

1 reference

Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study

21 January 2018

1 reference

Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis.

21 January 2018

1 reference

Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection

21 January 2018

1 reference

Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.

21 January 2018

1 reference

Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study

21 January 2018

1 reference

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).

21 January 2018

1 reference

Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy

21 January 2018

1 reference

Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study

21 January 2018

1 reference

Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study

21 January 2018

1 reference

A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.

21 January 2018

1 reference

Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study

21 January 2018

1 reference

Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).

21 January 2018

1 reference

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate

21 January 2018

1 reference

The correction of BMD measurements for bone strontium content.

21 January 2018

1 reference

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

21 January 2018

1 reference

Effects of weight, body composition, and testosterone on bone mineral density in HIV-infected women

21 January 2018

1 reference

Alendronate for osteoporosis in men with androgen-repleted hypogonadism

21 January 2018

1 reference

Alendronate for the Treatment of Osteoporosis in Men

21 January 2018

1 reference

Effects of a combined alendronate and calcitriol agent (Maxmarvil®) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

Comparison of Weekly Treatment of Postmenopausal Osteoporosis with AlendronateVersusRisedronate Over Two Years

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1K465

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18413693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference